Table 2.

Characteristics of CCFA Partner’s Ulcerative Colitis patients by age at baseline

Characteristics	Older (age ≥60) (n=368) Median (IQR) or %	Younger (age 18–59) (n=1622) Median (IQR) or %
Age (years)	65 (63–70)	38 (29–48)
Gender (% female)	59.0	73.2
Education (% >high school)	90.9	93.9
Race
Caucasian	97.3	91.9
African American	1.2	1.2
Other	1.5	6.8
Current smoking (% yes)	2.2	3.3
BMI	26.0 (23.3–29.4)	23.7 (21.3–27.4)
Disease duration (years)	16 (6–31)	7 (3–14)
Ever GI surgery (% yes)	13.6	11.8
Ever hospitalization (% yes)	39.7	47.4
Number hospitalizations	2 (1–3)	2(1–3)
Current medications
Biologic Anti-TNF	16.0	19.2
Immunomodulator*	18.5	24.0
Corticosteroids	9.6	15.4
5-ASA&	73.8	68.2
Remission (SCCAI^ ≤2) (% yes)	45.9	43.9
SCCAI	3 (1–4)	3 (1–5)
SIBDQ**	5.5 (4.6–6)	5 (4–5.8)

^*Immunomodulator defined as 6-mercaptopurine, azathioprine, or methotrexate

^&5-aminosalicylate

^{^}Simple clinical colitis activity index

^**Short inflammatory bowel diseases questionnaire